GleamWall
中文EN

TENX TENAX THERAPEUTICS, INC.

Pharmaceutical Preparations · Nasdaq · SEC CIK 34956 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY0.4%
TTM EPS YoY-87.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-64.2%
ROA-59.8%
ROIC (approx.)—
Asset turnover0.00x

Leverage & solvency

Liabilities / assets7.1%
Debt / equity0.00x
Current ratio14.01x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.75x
Accruals ratio-14.9%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$0$0
R&D expense$32.67M$12.71M
SG&A expense$23.71M$6.79M
Operating income-$56.38M-$19.49M
Interest expense$0$23,000
Income tax$0$0
Net income-$52.60M-$17.60M
EBITDA—-$19.49M
EPS (basic)-1.34-1.15
EPS (diluted)-1.34-1.15
Weighted avg. shares (diluted)39.22M15.27M
Balance sheet
Cash & equivalents$97.56M$94.85M
Current assets$104.23M$96.69M
Total assets$104.23M$96.69M
Current liabilities$7.16M$4.69M
Total liabilities$7.16M$4.69M
Shareholders' equity$97.07M$91.99M
Shares outstanding9.31M3.42M
Cash flow statement
Operating cash flow-$35.80M-$14.81M
Investing cash flow—$0
Financing cash flow$38.51M$99.87M
Depreciation & amortization—$0
Stock-based compensation$19.16M$1.12M

Free plan shows the latest 2 periods; Pro shows all 16 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.